-
- 抗原 See all CDKN1C 抗体
- CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This CDKN1C antibody is un-conjugated
-
应用范围
- Western Blotting (WB)
- 品牌
- BD Pharmingen™
- 产品特性
-
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing. - 纯化方法
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
- 免疫原
- p57[Kip2] Recombinant Human
- 克隆位点
- A120-1
- 亚型
- IgG1 kappa
- Top Product
- Discover our top product CDKN1C Primary Antibody
-
-
- 应用备注
- Applications for clone A120-1 include western blot analysis (1-2 µg/ml). SJCRH30 human rhabdomyosarcoma cells are suggested as a positive control (ATCC CRL-2061).
- 说明
-
Related Products: ABIN967389
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 0.5 mg/mL
- 缓冲液
- Aqueous buffered solution containing ≤0.09 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
- 储存方法
- Store undiluted at 4°C.
-
-
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)." in: Oncogene, Vol. 11, Issue 2, pp. 211-9, (1995) (PubMed).
: "Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution." in: Genes & development, Vol. 9, Issue 6, pp. 639-49, (1995) (PubMed).
: "p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene." in: Genes & development, Vol. 9, Issue 6, pp. 650-62, (1995) (PubMed).
: "
-
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)." in: Oncogene, Vol. 11, Issue 2, pp. 211-9, (1995) (PubMed).
-
- 抗原
- CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))
- 别名
- p57 Kip2 (CDKN1C 产品)
- 背景
- Cyclin dependent kinase inhibitors (CdkIs) inhibit progression through the cell cycle by binding to cyclins, Cdks, or cyclin-Cdk complexes. CdkIs are classified into two groups based on protein structure. p57[Kip2] belongs to a group that also includes p27[Kip1] and p21 (also known as Sdi1, Cip1, Waf1 and Pic1). Members of this group have a homologous amino-terminal Cdk inhibitory domain. Members of the second group [p16 (INK4A), p15 (INK4B), p18 (INK4C), and p19 (INK4D)] contain ankyrin repeat motifs. p57[Kip2] is a potent, tight-binding inhibitor of several G1 and S phase cyclin-Cdk complexes including cyclin E-Cdk2, cyclin D2-Cdk4, and cyclin A-Cdk2. It inhibits the mitotic cyclin B1-Cdk1 complex to a lesser extent. mRNA studies suggest that p57[Kip2] expression is tissue-specific, the highest levels have been found in embryonic and adult skeletal muscle, heart, kidney, lung, eye and brain. This is in contrast to the widespread tissue expression of p27[Kip1] and p21 mRNA. The expression of p57[Kip2] to primarily terminally differentiated cells suggests that p57[Kip2] may play a specialized role in cell cycle control. Clone A120-1 reacts with human p57[Kip2]. Recombinant human p57[Kip2] was used as immunogen.
- 分子量
- 57 kDa
- 途径
- Cell Division Cycle, Dopaminergic Neurogenesis
-